Skip to content
Screener

Pre-Tax Income at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
-$91M
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$43.09M+7.1%
Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses214,847167,755429,351321,553
Income (loss) from operations41,30026,675(8,301)30,091
Interest and other income4,6315,0179,51711,219
Income before income taxes45,93131,6921,21641,310
Income tax (expense) benefit(2,944)3,45710,01014,386
Net income42,98735,14911,22655,696
Net income attributable to common stockholders42,14134,61111,01754,918
Basic net income per common share$0.40$0.33$0.11$0.53

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's pre-tax income?
Corcept Therapeutics (CORT) reported pre-tax income of $45.93M in Q2 2026.
How has Corcept Therapeutics's pre-tax income changed year-over-year?
Corcept Therapeutics's pre-tax income increased by 44.9% year-over-year, from $31.69M to $45.93M.
What is the long-term trend for Corcept Therapeutics's pre-tax income?
Over 4 years (2021 to 2025), Corcept Therapeutics's pre-tax income has grown at a -14.6% compound annual growth rate (CAGR), from $125.01M to $66.46M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Corcept Therapeutics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude